Mersana Therapeutics, Inc. Stock News

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette - SVP, IR Martin Huber - President & CEO Mohan Bala - SVP, Chief Development Officer Brian DeSchuytner - CFO & COO Conference Call Participants Tara Bancroft - TD Cowen Yen-Der Li - Leerink Partners Charles Zhu - LifeSci Capital Ashiq Mubarack - Citi Yige G...

CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2024.

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended Septe...

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Martin Huber - President & CEO Brian DeSchuytner - CFO & COO Jason Fredette - SVP, IR Conference Call Participants Tara Bancroft - TD Cowen Jonathan Chang - Leerink Partners Ashiq Mubarack - Citi Michael Schmidt - Guggenheim Charles Zhu - LifeSci Capital Colleen Kusy - Robe...

CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2024.

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June...

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) --  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: